Ulbig M, Schneider T
Universitäts-Augenklinik, Würzburg, Bundesrepublik Deutschland.
Fortschr Ophthalmol. 1991;88(5):431-3.
Lovastatin is an inhibitor of HMG-Co A reductase, a key enzyme in cholesterol biosynthesis. It is of therapeutic value in hypercholesterolemia type IIa and leads to decreased levels of low-density lipoproteins in serum. Treatment with high doses of lovastatin has been reported to induce cataract formation in dogs. The goal of the ongoing prospective clinical study is to evaluate whether cataract formation is caused in humans by therapeutic doses of lovastatin. So far 28 patients (average age 44 years) suffering from hypercholsterolemia have entered the study. Besides thorough slit-lamp investigations in all patients, best corrected visual acuity and contrast sensitivity for five different spatial frequencies were measured. A reduction in contrast sensitivity is a sensitive indicator for opacities of lens and cornea. During a mean follow-up of 37 weeks (range 5-62 weeks) with a mean total dose of 15 g (range 2-26 g), no cataract formation or decreased contrast sensitivity has so far been observed.
洛伐他汀是3-羟基-3-甲基戊二酰辅酶A还原酶的抑制剂，该酶是胆固醇生物合成中的关键酶。它对IIa型高胆固醇血症具有治疗价值，并能降低血清中低密度脂蛋白的水平。据报道，用高剂量的洛伐他汀治疗可导致犬类白内障形成。正在进行的前瞻性临床研究的目的是评估治疗剂量的洛伐他汀是否会在人类中导致白内障形成。到目前为止，28名患有高胆固醇血症的患者（平均年龄44岁）已进入该研究。除了对所有患者进行全面的裂隙灯检查外，还测量了最佳矫正视力和五种不同空间频率下的对比敏感度。对比敏感度降低是晶状体和角膜混浊的敏感指标。在平均37周（范围5-62周）的随访期间，平均总剂量为15克（范围2-26克），到目前为止，尚未观察到白内障形成或对比敏感度降低。
